News

Charles River Labs Attain 100% Renewable Electricity Feat

Pharmaceutical and microbial testing company- Charles River Laboratories happens to be now operating all of its international branches with completely 100% renewable electricity as of Q1 of 2024. It is worth noting that the UK-based company went on to reach...

All Infinity Laboratories Facilities Are Now ISO Certified

Infinity Laboratories has gone on to achieve successful accreditation across all its sites pertaining to their ISO/IEC standards, thereby highlighting its commitment to making sure that high standards of excellence and quality within the field of chemical and microbiology...

Effect of The EU Sustainability Directive On Supply Chains

It is worth noting that 84% of pharma and healthcare companies go on to consider that the new EU Corporate Sustainability Due Diligence Directive- CDDDD happens to be nothing short of an opportunity so as to sync human rights...

AI In Supply Chain Management Across Bio & Pharma Sector

The Drug, Chemical, & Associated Technologies Association- DCAT has gone on to recently release a study from DCAT Research & Benchmarking- The emerging role of Artificial Intelligence in Supply Chain Management. The fact is that the bio- and pharma sectors...

TriLink Invests in New RNA Innovation Center at Johns Hopkins

TriLink BioTechnologies, a Maravai LifeSciences company and global provider of life science reagents and services, has joined forces with Johns Hopkins University to accelerate transformational research in RNA therapeutics and discovery by establishing a new center within the Johns...

Sartorius, Sanofi Partner to Develop End-to-End Platform for Downstream Process Intensification

Life science group Sartorius is collaborating with biopharmaceutical company Sanofi to develop an end-to-end platform for integrated and continuous downstream bioprocessing (ICB). Integrated continuous biomanufacturing is an advanced approach to the production of biopharmaceuticals, which aims to maximize efficiency by...

AbbVie, Gilgamesh Pharma Partner on Next-Gen Psychiatric Therapies

AbbVie and Gilgamesh Pharmaceuticals entered a collaboration and option-to-license agreement to develop next-generation therapies for psychiatric disorders. This collaboration will leverage AbbVie's expertise in psychiatry and Gilgamesh's research platform to discover novel neuroplastogens. Under the agreement, the companies have agreed...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read